Indication

Erectile dysfunction

Erectile dysfunction is a male sexual dysfunction characterized by the recurrent or persistent inability to achieve or maintain a penile erection of sufficient rigidity for satisfactory sexual intercourse. Read more about Erectile dysfunction

97 drugs 60 manufacturers

Advertisement

Drugs that treat it

Common Erectile dysfunction therapies.

Showing 28–36 of 97 drugs

TADALAFIL

AGENTS TO TREAT ERECTILE DYSFUNCTION, CGMP-TYPE·BENIGN PROSTATIC HYPERPLASIA WITH LOWER URINARY TRACT SYMPTOM·+1
AJANTA PHARMA L

TADALAFIL

AGENTS TO TREAT ERECTILE DYSFUNCTION, CGMP-TYPE·BENIGN PROSTATIC HYPERPLASIA WITH LOWER URINARY TRACT SYMPTOM·+1
UNICHEM PHARMAC

TADALAFIL

AGENTS TO TREAT ERECTILE DYSFUNCTION, CGMP-TYPE·BENIGN PROSTATIC HYPERPLASIA WITH LOWER URINARY TRACT SYMPTOM·+1
CAMBER PHARMACE

TADALAFIL

AGENTS TO TREAT ERECTILE DYSFUNCTION, CGMP-TYPE·BENIGN PROSTATIC HYPERPLASIA WITH LOWER URINARY TRACT SYMPTOM·+1
BUREL PHARMACEU

TADALAFIL

AGENTS TO TREAT ERECTILE DYSFUNCTION, CGMP-TYPE·BENIGN PROSTATIC HYPERPLASIA WITH LOWER URINARY TRACT SYMPTOM·+1
DR.REDDY'S LAB

TADALAFIL

BENIGN PROSTATIC HYPERPLASIA WITH LOWER URINARY TRACT SYMPTOM·+1
APOTEX CORP

TADALAFIL

AGENTS TO TREAT ERECTILE DYSFUNCTION, CGMP-TYPE·BENIGN PROSTATIC HYPERPLASIA WITH LOWER URINARY TRACT SYMPTOM·+1
PRASCO LABS

TADALAFIL

BENIGN PROSTATIC HYPERPLASIA WITH LOWER URINARY TRACT SYMPTOM·+1
LUPIN PHARMACEU

TADALAFIL

AGENTS TO TREAT ERECTILE DYSFUNCTION, CGMP-TYPE·BENIGN PROSTATIC HYPERPLASIA WITH LOWER URINARY TRACT SYMPTOM·+1
ZYDUS PHARMACEU
Filter & compare in the drug finder →Opens the drug finder with Erectile dysfunction preselected.

News & literature

Coming soon

Related codes

Coming soon
Coming soon

About Erectile dysfunction.

Erectile dysfunction is a male sexual dysfunction characterized by the recurrent or persistent inability to achieve or maintain a penile erection of sufficient rigidity for satisfactory sexual intercourse.

It predominantly affects adult men, with incidence and prevalence increasing with advancing age and comorbid health conditions.

Pathophysiologically, the disorder involves disruption within the male reproductive and cardiovascular systems, often arising from impaired cavernosal arterial inflow, endothelial dysfunction, deficient smooth muscle relaxation, veno-occlusive failure, or neurohormonal and psychogenic dysregulation.

Commonly linked to underlying systemic vascular disease, diabetes mellitus, neurologic trauma, or medication effects, it reflects an overall impairment in the coordinated vascular and neural signaling required for tumescence.

Personalize your experience

Follow Erectile dysfunction and get updates as they land.

Create a free account

Follow an indication and get alerts when its drugs, labels, or guidelines change

Save any drug on this page to your favorites, synced across devices

AI-curated peer-reviewed research, summarized for your specialty

A morning digest of indication-relevant updates, when you want it